NCT05641064View on ClinicalTrials.gov

Evaluation of Intraoperative Dexmedetomidine Use in Patients Undergoing Surgical Aortic Valve Replacement

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

September 22, 2024

Study Completion Date

September 22, 2024

Conditions
Systemic Inflammatory ResponseAortic Valve Stenosis
Interventions
DRUG

Placebo

Continuous infusion of saline starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion

DRUG

Dexmedetomidine 0.5mcg/kg/h

Continuous infusion of dexmedetomidine in 0.5mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion

DRUG

Dexmedetomidine 1 mcg/kg/h

Continuous infusion of dexmedetomidine in 1mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion

Trial Locations (1)

10000

University hospital Dubrava, Zagreb

All Listed Sponsors
lead

University Hospital Dubrava

OTHER